Cholangiocarcinoma

Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma. Read More ›

A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma. Read More ›

Investigators found the addition of toripalimab to a gemcitabine-based chemotherapy regimen as first-line treatment of advanced biliary tract cancers demonstrated encouraging efficacy. Read More ›

The phase 2 STAMP study revealed negligible differences in disease-free survival and overall survival between adjuvant gemcitabine/cisplatin versus capecitabine in lymph node–positive extrahepatic cholangiocarcinoma but found increased grade 3/4 adverse events with gemcitabine/cisplatin. Read More ›

A systematic review of phase 2 and 3 clinical trials for biliary tract cancers revealed quality-of-life assessments were not routinely included as trial outcomes. Read More ›

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival. Read More ›

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters. Read More ›

Analysis of the phase 3 ABC-06 trial revealed limited prognostic utility of the tumor marker CA19.9 after initiation of FOLFOX. Read More ›

During a session at the Cholangiocarcinoma (CCA) Foundation 2022 annual meeting, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA (ctDNA) in early detection and disease monitoring for CCA. Read More ›

Immune checkpoint inhibitor therapy in advanced biliary tract cancer (BTC) is associated with limited clinical activity. Read More ›